Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis

Rønnstad, Amalie Thorsti Møller; Halling, Anne‐Sofie; Hamann, Carsten R.; Skov, Lone; Egeberg, Alexander; Thyssen, Jacob P.

doi:10.1016/j.jaad.2018.03.017

Cited by 223 publications

(232 citation statements)

References 71 publications

Supporting

Mentioning

200

Contrasting

Unclassified

Order By: Relevance

“…Within LIFE cohort, significantly more of subjects with AE than controls reached scores indicating depression. The frequency in our study group (9.3%) was within the range of other studies, reporting on prevalences between 9% and 15% of depressive disorders in subjects with AE …”

Section: Discussionsupporting

confidence: 87%

“…In our study group, the odds for anxiety in AE were not as high as in subjects with history of cancer (OR 1.5 vs. 1.9) but higher than in those with history of myocardial infarction, stroke or diabetes mellitus. Pooled odds ratios from international studies for anxiety in AE were 2.19 . It was shown that increased anxiety scores were associated with AE severity, which, however, could not be assessed in our study.…”

Section: Discussioncontrasting

confidence: 65%

“…In our study, the odds for depression in subjects with AE were remarkably close to values from subjects with history of cancer. A recently published meta‐analysis showed an association of AE with depression with pooled odd ratios of 2.19 . We suppose that the lower odds in our study (OR 1.5) are due to broader spectrum of disease severity in our subjects, while studies included within the meta‐analysis were mainly those with moderate–severe type of the disease …”

Section: Discussionmentioning

confidence: 52%

“…Overall, there is increasing evidence that AE is more than a skin disease and may be associated with several, non‐atopic comorbidities. One might speculate that itch, skin pain and sleep disturbances in combination with typical AE skin lesions, cause psychologic distress which may result in development of depression, anxiety and/or impaired QoL . There is still debate whether the depressive and anxious symptoms result from physical discomfort and psychosocial burden of the skin disease or whether these disorders are based on shared inflammatory pathomechanisms …”

Section: Discussionmentioning

confidence: 99%

“…About 15% of them were from Germany . Suicidal ideation was reported to occur as a consequence of depression and anxiety …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Depression, anxiety and quality of life in subjects with atopic eczema in a population‐based cross‐sectional study in Germany

Treudler¹,

Zeynalova

Riedel-Heller

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Atopic eczema (AE) may be associated with several mental health problems. In Germany, existing data from selected patient cohorts may lead to misestimation of the problem. Objectives We aimed to cross‐sectionally determine associations of AE with depression, anxiety, quality of life (QoL) and social interactions in subjects from the population‐based LIFE‐Adult‐Study. Methods Subjects underwent standardized interviews (medical history) and answered standardized questionnaires [Centre of Epidemiologic studies‐Depression scale (CES‐D), Generalized Anxiety Disorder (GAD‐7), Lubben Social Network Scale (LSNS), Short Form Health Survey (SF‐8)]. We compared data from subjects with AE with those from subjects with selected other chronic/disabling diseases (cardiovascular, diabetes, cancer) and adjusted for selected sociodemographic parameters. Multivariate binary logistic regression was used for categorical variables, linear regression for continuous variables. Results Out of 9104 adults included (57% female, median age 54 years), 372 (4.1%) had a history of AE. Compared with controls, subjects with AE showed higher scores for depressive symptoms (9.3% vs. 6.3%; P < 0.001) and anxiety (8.4% vs. 5.6%, P < 0.001). Odds ratio (OR) was 1.5 [CI 1.0; 2.3] (P = 0.031) for depression, which was comparable to OR in patients with a history of cancer (OR 1.6 [1–2.3], P = 0.001. OR for anxiety in AE was 1.5 [1.0; 2.2], P < 0.049, which was slightly higher than in diabetes mellitus (OR 1.2) and stroke (OR 1.4). Other than in diabetes and/or stroke, we did not find a significant association between AE and social isolation. QoL scores were lower in AE than in controls (mean 46.9 vs. 48.0, P < 0.001 for physical and 50.6 vs. 52.5, P < 0.001 for mental components). Conclusions Subjects with AE showed higher values for depression and anxiety as well as lower QoL scores compared to controls. With regard to depression, odds in AE and cancer were hardly different. Medical care of AE patients should therefore include mental health evaluation and treatment if indicated.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussioncontrasting

confidence: 65%

Section: Discussionmentioning

confidence: 52%

Section: Discussionmentioning

confidence: 99%

“…About 15% of them were from Germany . Suicidal ideation was reported to occur as a consequence of depression and anxiety …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Depression, anxiety and quality of life in subjects with atopic eczema in a population‐based cross‐sectional study in Germany

Treudler¹,

Zeynalova

Riedel-Heller

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

et al. 2020

Self Cite

View full text Add to dashboard Cite

an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic dermatitis (AD). OBJECTIVE To investigate the efficacy and safety of abrocitinib in adolescents and adults with moderate-to-severe AD in an identically designed trial. DESIGN, SETTING, AND PARTICIPANTS This phase 3, double-blinded, placebo-controlled, parallel-group randomized clinical trial included patients 12 years or older with a clinical diagnosis of moderate-to-severe AD for at least 1 year and inadequate response to topical medications given for at least 4 weeks within 6 months. Patients were enrolled from 115 centers in Australia,

show abstract

Association of Atopic Dermatitis Severity With Learning Disability in Children

et al. 2021

View full text Add to dashboard Cite

IMPORTANCERecent population-based data indicate that atopic dermatitis (AD) is associated with learning disability (LD) in children, but the association between AD severity and LD is unknown.OBJECTIVE To evaluate the association of AD severity with learning problems in children with AD. DESIGN, SETTING, AND PARTICIPANTSThis cross-sectional study analyzed data of US participants enrolled in the Pediatric Eczema Elective Registry (PEER) between November 1, 2004, and November 30, 2019. Participants were children aged 2 to 17 years at registry enrollment with physician-confirmed diagnosis of AD and had completed 10 years of follow-up in PEER.EXPOSURES Atopic dermatitis severity measured by both the Patient-Oriented Eczema Measure (POEM) score and self-report. The POEM scores ranged from 0 to 28, with strata of clear or almost clear skin (0-2), mild (3-7), moderate (8-16), severe (17-24), and very severe (25-28). Self-reported AD severity was categorized as clear skin or no symptoms, mild, moderate, or severe. MAIN OUTCOMES AND MEASURESLearning disability diagnosed by a health care practitioner, as reported by the participants or their caregivers. RESULTSAmong the 2074 participants with AD (1116 girls [53.8%]; median [interquartile range (IQR)] age, 16.1 [13.9-19.5] years at 10-year follow-up), 169 (8.2%) reported a diagnosis of an LD. Children with an LD vs those without an LD were more likely to have worse AD severity, as measured by the median (IQR) total POEM score (5 [1-10] vs 2 [0-6]; P < .001), POEM severity category (moderate AD: 50 of 168 [29.8%] vs 321 of 1891 [17.0%]; severe to very severe AD: 15 of 168 [8.9%] vs 85 of 1891 [4.5%]; P < .001); and self-report (moderate AD: 49 of 168 [29.2%] vs 391 of 1891 [20.7%]; severe AD: 11 of 168 [6.5%] vs 64 of 1891 [3.4%]; P < .001).In multivariable logistic regression models adjusted for sex, age, race/ethnicity, annual household income, age of AD onset, family history of AD, and comorbid conditions, participants with mild AD (odds ratio [OR], 1.72; 95% CI, 1.11-2.67), moderate AD (OR, 2.09; 95% CI, 1.32-3.30), and severe to very severe AD (OR, 3.10; 95% CI,) on the POEM were all significantly more likely to have reported an LD than those with clear or almost clear skin. CONCLUSIONS AND RELEVANCEThis cross-sectional study found that worse AD severity was associated with greater odds of reported LD, independent of socioeconomic characteristics, AD onset age, and other related disorders. Although additional prospective and mechanistic studies are needed to clarify the association of AD with learning, the findings suggest that children with more severe AD should be screened for learning difficulties to initiate appropriate interventions that can mitigate the consequences of an LD.

show abstract

Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis

Abstract: Depression, anxiety, and suicidal ideation should be considered by doctors when treating patients with AD. Because AD disease improvement appears to reduce these risks, this should be a priority.

Cited by 223 publications

References 71 publications

Depression, anxiety and quality of life in subjects with atopic eczema in a population‐based cross‐sectional study in Germany

Depression, anxiety and quality of life in subjects with atopic eczema in a population‐based cross‐sectional study in Germany

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

Association of Atopic Dermatitis Severity With Learning Disability in Children

Contact Info

Product

Resources

About